Aurora Bio is developing peptope and CAR-M immunotherapies against systemic amyloidosis that does not affect the central nervous system. This excludes diseases such as Parkinson’s and Alzheimer’s, but it includes transthyretin amyloidosis, a deadly disease that kills the very old. Its therapy is designed to attract immune cells to amyloids, spurring them to absorb and destroy these harmful protein aggregates.
The company is also developing a radiotracer peptide, P5+ 14, which is designed to bind to amyloids and trace their presence. This radiotracer is currently in Phase 1 human clinical trials, but this is a diagnostic tool and not a therapy.